-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 17, the Insight database showed that the SYSA1801 injection, a class 1 new drug of CSPC Jushi Biologics, started clinical trials for CLDN18.
On the same day, CSPC announced that its subsidiary NovaRock has reached a cooperation with Flame Biosciences, Inc.
In this transaction, CSPC received a down payment of US$7.
From the Insight database
Claudin 18.
Claudin 18.
According to the Insight database, there are currently 19 biological drugs targeting Claudin 18.
Claudin 18.
Gastric cancer is a cancer with a higher incidence in Asian countries such as China, Japan and South Korea
CSPC's Claudin 18.
CSPC's Claudin 18.
In November last year, SYSA1801 was approved as an orphan drug by the FDA for gastric cancer and gastroesophageal junction cancer
NBL-015 is a fully human anti-Claudin 18.
At present, NBL-015 has been approved by the US FDA as an orphan drug for the treatment of pancreatic cancer and gastric cancer (including cancer of the esophagus and gastric junction), and its IND application has also been approved by the US FDA in May 2021
NovaTE is a novel tumor antigen and CD-137 dual antibody technology platform, which aims to selectively activate T cells with antigen experience in the tumor microenvironment
